Skip to main content

Table 1 Demographics and clinical data for study participants

From: VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome

  Controls aDS pDS dDS
N 20 40 19 21
Age-at-analysis, years 47 (11, 24–64) 35 (9, 22–57)b 52 (4, 45–60) 52 (5, 42–62)
% Female 60% 40% 42% 38%
% Mild or moderate ID 0% 83% 79% 67%
CAMCOG scorea NA 80/107 (11, 55–96, n = 31) 70/107 (13.8, 41–92, n = 11)c 59/107 (13.9, 39–87, n = 10)c
mCRT score (immediate)a NA 35/36 (1.5, 30–36, n = 30) 20/36 (11.2, 0–36, n = 12)c 15/36 (7.9, 0–32, n = 11)c
mCRT score (delayed)a NA 12/12 (0.9, 8–12, n = 31) 6/12 (3.8, 0–12, n = 13)c 4/12 (3.3, 0–12, n = 11)c
CSF Aβ42:40 ratio 0.11 (0.01, 0.08–0.12) 0.09 (0.02, 0.04–0.12)b 0.05 (0.01, 0.03–0.08)b 0.05 (0.01, 0.04–0.08)b
CSF p-tau pg/ml 36 (8, 22–54) 35 (24, 10–122) 145 (86, 22–304)b 158 (82, 31–323)b
CSF t-tau pg/ml 243 (57, 167–366) 295 (166, 86–671) 936 (658, 118–2565) b 959 (500, 212–1988) b
CSF NFL pg/ml NA 355 (234, 65–1036) 1071 (767, 313–3123) 1387 (832, 627–3957)
  1. Mean values (standard deviation, range) are given for each variable across clinical groups. NA, not available. aIn individuals with mild/moderate intellectual disability (ID) only. bp < 0.05 compared to controls. cp < 0.05 compared to aDS